SYN Synthetic Biologics, Inc. Commo

0.87
+0.02  (3.23%)
Previous Close 0.84
Open 0.88
Price To book 0.00
Market Cap 80.03M
Shares 92,172,000
Volume 450,571
Short Ratio 4.86
Av. Daily Volume 1,157,110

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 2 trial commenced October 2015. 12 week data met endpoints. Phase 2b/3 planned for 1Q 2017.
SYN-010
Constipation-Predominant Irritable Bowel Syndrome (C-IBS)
Pending. Partner Meda has received the go-ahead from the FDA to conduct a Phase 2 proof of concept trial
Flupirtine
Fibromyalgia
License terminated following lack of efficacy shown February 2016
Trimesta
Relapsing-remitting MS in women
Phase 2b topline data released January 5, 2017. Primary endpoint met. Phase 3 trial to be initiated end of 2017.
SYN-004
C. difficile Infection

Latest News

  1. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  2. Synthetic Biologics C. Difficile Drug Trial Succeeds
  3. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  4. Synthetic Biologics' C. difficile mid-stage study meets main goal
  5. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  6. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)
  7. Synthetic Biologics to Present at the Biotech Showcase™ 2017 Conference
  8. Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
  9. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
  10. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences
  11. Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences
  12. Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
  13. Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants
  14. SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
  15. Nokia, Teva Plunge into Tuesday’s 52-Week Low Club
  16. Synthetic Biologics Prices Secondary Offering
  17. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
  18. Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants
  19. Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants
  20. SYNTHETIC BIOLOGICS, INC. Financials

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17524044
  2. 8-K - Current report 17515767
  3. 8-K - Current report 17508669
  4. 8-K - Current report 162031781
  5. SC 13G - Statement of acquisition of beneficial ownership by individuals 162004497
  6. 424B5 - Prospectus [Rule 424(b)(5)] 162000526
  7. 8-K - Current report 162000511
  8. 424B5 - Prospectus [Rule 424(b)(5)] 161996950
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 161963239
  10. 8-K - Current report 161963231